Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States

Pharmacotherapy
Jessica L AdamsMelanie R Nicol

Abstract

The antiretroviral combination of emtricitabine-tenofovir disoproxil fumarate (FTC/TDF) was approved by the U.S. Food and Drug Administration for use as pre-exposure prophylaxis (PrEP) in individuals at high risk for acquiring human immunodeficiency virus (HIV) in July 2012. Since then, Centers for Disease Control and Prevention guidelines for the use of PrEP have been published and implemented into clinical practice throughout the United States. A number of published open-label and PrEP demonstration projects have evaluated the real-world use of PrEP including analysis of the barriers to its use and addressing major concerns. Despite the approval of FTC/TDF for PrEP, its use for this indication relies on patient and provider acceptance, and its effectiveness requires patient adherence and retention in care during periods of high-risk behaviors. Concerns regarding the use of PrEP in healthy individuals persist and include medication adverse effects including renal dysfunction and bone mineral density loss; risk compensation leading to HIV infections, sexually transmitted infections, and unintended pregnancies; and the development of drug resistance in the event of seroconversion. The cost-effectiveness of PrEP continues to be a...Continue Reading

References

Nov 26, 2010·The New England Journal of Medicine·Robert M GrantUNKNOWN iPrEx Study Team
Apr 27, 2012·Patient Preference and Adherence·Parya SaberiJennifer M Cocohoba
Jul 13, 2012·The New England Journal of Medicine·Jared M BaetenUNKNOWN Partners PrEP Study Team
Jul 13, 2012·The New England Journal of Medicine·Michael C ThigpenUNKNOWN TDF2 Study Group
Jun 29, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Peter J RuaneKitty Yale
Dec 10, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Maile Y KarrisPhilip M Polgreen
Oct 25, 2014·Journal of the American Pharmacists Association : JAPhA·Kristy M ShaeerPatrick Hardigan
Sep 4, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jonathan E VolkC Bradley Hare
Dec 2, 2015·The New England Journal of Medicine·Jean-Michel MolinaUNKNOWN ANRS IPERGAY Study Group
Feb 24, 2016·The New England Journal of Medicine·Jared M BaetenUNKNOWN MTN-020–ASPIRE Study Team
Aug 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Emmanuel F DraboNeeraj Sood
Sep 7, 2016·Journal of the American Pharmacists Association : JAPhA·Elizabeth J UnniWilliam Kuykendall
Sep 16, 2016·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Sybil G HosekUNKNOWN Adolescent Trials Network (ATN) for HIVAIDS Interventions
Feb 2, 2017·The New England Journal of Medicine·David C KnoxDarrell H S Tan
Apr 4, 2017·The Journal of Antimicrobial Chemotherapy·Mackenzie L CottrellAngela D M Kashuba
Jul 15, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Charlotte-Paige RolleColleen F Kelley
Sep 14, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Helen L ZhangMehri S McKellar
Sep 19, 2017·The Lancet. HIV·Elske HoornenborgUNKNOWN Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Consortium (H-TEAM)
Oct 28, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Martin MarkowitzHiroshi Mohri
Dec 7, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Michael E NewcombBrian Mustanski
Dec 7, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Puja van EppsMichael E Ohl
Dec 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David J MooreSheldon R Morris
Apr 27, 2018·Current Opinion in HIV and AIDS·Martin Markowitz, Stefan G Sarafianos
May 24, 2018·Journal of the American Pharmacists Association : JAPhA·Olihe Okoro, Lisa Hillman
Jul 26, 2018·JAMA : the Journal of the American Medical Association·Michael S SaagPaul A Volberding
Oct 9, 2018·The Journal of Infectious Diseases·Elizabeth C PasipanodyaUNKNOWN California Collaborative Treatment Group (CCTG) TAPIR Study Team

❮ Previous
Next ❯

Citations

May 17, 2019·Nature·Laura Dwyer-LindgrenSimon I Hay
Jul 17, 2019·Drugs·Ioannis Hodges-MameletzisRachel Baggaley
Apr 2, 2020·Advances in Therapy·Kenneth H MayerDavid Malebranche
Jul 24, 2020·Journal of Doctoral Nursing Practice·Michelle Peters Zappas, Ruth Madden Foreman
Aug 12, 2020·Public Health Reports·Donna Hubbard McCreePaul J Weidle
Feb 10, 2021·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Gabriela Leite BaggioPaulo Henrique Couto Souza

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.